Join to access to all OVN content. Join for Free

Results for 'oncology drug trials'

...
OVN Avatar Forbes Books Press Release Official
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Sep 8th • 5 mins read

...
Partner Avatar Tom Caravela
Mastering the First Impression

Jan 28th • 2 mins read

...
Partner Avatar Tom Caravela
Job Search Checklist for Aspiring Medical Science Liaisons

May 16th • 2 mins read

...
Partner Avatar Tom Caravela
10 Ways to Make an Impact on a Phone Interview

Apr 8th • 1 min read

...
Partner Avatar Bridget Rasmusson
Presentation Nails and Fails: 7 Tips to Ace Your Next MSL Presentation

Oct 11th • 1 min read

...
Partner Avatar Tom Caravela
MSL Evolution: New Trends and Titles That May Emerge

Apr 4th • 1 min read

...
Partner Avatar Bridget Rasmusson
Positioning Yourself to Become an MSL in 2022

Dec 20th • 10 mins read

...
Partner Avatar iNIZIO
Virtual Oncology MSL Team Increases KOL Engagement by 120%

Sep 2nd • 1 min read

...
Partner Avatar iNIZIO
Clinical Educator Oncology Program Improves Adherence by 29%​

Sep 2nd • 1 min read

...
Partner Avatar iNIZIO
Transforming oncology: Five frontiers driving progress in cancer care

May 15th • 5 mins read

...
Partner Avatar iNIZIO
Expert perspectives live from ASCO® 2025

Jul 1st • 1 min read

...
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

May 5th • 18 mins read

...
OVN Avatar Charles Oo, Barbara Ameer
Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic

Apr 28th • 2 mins read

...
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Apr 12th • 10 mins read

...
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Apr 19th • 8 mins read

...
OVN Avatar A. Haslam, M.S. Kim, V. Prasad
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Apr 19th • 7 mins read

...
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 6th • 12 mins read

...
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Apr 7th • 4 mins read

...
OVN Avatar Pai, Rekha
Advances in basic research in oncology in 2020: Bridging basic science and clinical care

Mar 23rd • 1 min read

...
OVN Avatar Adela Rodriguez, Francis Esposito, Helena Oliveres, Ferran Torres and Joan Maurel
Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?

Feb 10th • 3 mins read

Related Topics

Loading...